BIODESIX INC
No SEC Form 4 filings for $BDSX in the last 30 days.
See all $BDSX insider activity →Biodesix (BDSX) will release Q3 2026 financial results on Nov. 5 after market close, followed by a conference call at 4:30 p.m. ET. The company, which focuses on diagnostic solutions, will discuss results and provide a business update. A webcast replay will be available post-call.
Biodesix, Inc. (BDSX) announced the American College of Chest Physicians (CHEST) published a new framework for lung nodule programs, featuring its Nodify Lung® tests. The six-step plan, developed by a multidisciplinary panel, emphasizes biomarker testing for risk assessment. Biodesix's CEO highlighted the validation of their tests in the framework, which was presented at the 2026 CHEST Annual Meeting.
Biodesix (NASDAQ:BDSX) announced the addition of Digital Diagnostics to its lung testing platform, combining blood-based biomarkers, imaging, and AI. The first radiomics-based test, developed with Vanderbilt University, is expected to launch in 2028. The company has received IRB approval for a clinical study and is engaging with the FDA and Medicare for regulatory and commercialization support.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning BDSX (BIODESIX INC). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent BDSX coverage spans earnings, market movers and technology.
The announcement sets the timing for the upcoming earnings release, likely prompting short-term positioning ahead of the call.
Potential increase in demand for Biodesix's Nodify Lung test as guidelines endorse its use.
The announcement introduces a new multimodal diagnostic offering, potentially expanding revenue streams and positioning the company in AI-driven imaging.
Robust earnings beat supports continued bullish bias.
Revenue growth supports bullish view; price may continue upward trend.
AlphAI scores every news story that mentions BDSX with an AI model for sentiment and relevance, and aggregates insider trades from BIODESIX INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Biodesix (BDSX) will release Q3 2026 financial results on Nov. 5 after market close, followed by a conference call at 4:30 p.m. ET. The company, which focuses on diagnostic solutions, will discuss results and provide a business update. A webcast replay will be available post-call.
1 min readBiodesix, Inc. (BDSX) announced the American College of Chest Physicians (CHEST) published a new framework for lung nodule programs, featuring its Nodify Lung® tests. The six-step plan, developed by a multidisciplinary panel, emphasizes biomarker testing for risk assessment. Biodesix's CEO highlighted the validation of their tests in the framework, which was presented at the 2026 CHEST Annual Meeting.
2 min readBiodesix (NASDAQ:BDSX) announced the addition of Digital Diagnostics to its lung testing platform, combining blood-based biomarkers, imaging, and AI. The first radiomics-based test, developed with Vanderbilt University, is expected to launch in 2028. The company has received IRB approval for a clinical study and is engaging with the FDA and Medicare for regulatory and commercialization support.
1 min readSummit Therapeutics (SMMT) +7% on positive Phase III trial data; Celularity (CELU) +15% despite Nasdaq compliance issue; Biodesix (BDSX) +8% on Q2 revenue growth; Cardiol Therapeutics (CRDL) +12% with narrowed Q2 loss; Edesa Biotech (EDSA) +11% after public offering announcement.
3 min readSeveral biotech stocks hit 52-week highs on August 25, 2026. Generate Biomedicines (GENB) rose 15% to $22.67, despite a wider net loss. Biodesix (BDSX) climbed 10% to $30, reporting a 34% revenue increase. CareDx (CDNA) gained 6%, with Medicare coverage for its transplant tests. Cumberland Pharmaceuticals (CPIX) rose 10% to $8.70, advancing Ifetroban in trials. Cardiol Therapeutics (CRDL) increased 7% to $2.02, with CardiolRx in Phase 3 trials.
3 min readBiodesix (BDSX) hit a 52-week high of $29.18, up over 90% in three months. Q2 2026 revenue rose to $26.9M from $20.1M in Q2 2025, showing growth.
1 min readBiodesix (BDSX) reported Q2 2026 results and discussed clinical demand drivers for its Nodify lung nodule biomarkers. The company said March publication of a lung nodule validation study increased Nodify CDT orders for nodules as small as 4 mm. Q2 revenue rose 34% to $26.9M, diagnostic testing revenue $25.4M (+42%), gross margin 82%, and net loss was $7.3M. Full-year revenue outlook remains $108M to $114M.
7 min readSCHULER JACK W purchased 15,000 indirectly-held shares of BIODESIX INC (BDSX) at $24.47 ($0.37M total) on 2026-08-12.
1 min readSCHULER JACK W purchased 27,600 indirectly-held shares of BIODESIX INC (BDSX) at an average of $24.13 ($24.01–$24.25, $0.67M total) across 2 trades over 2026-08-10 to 2026-08-11.
2 min readBiotech stocks hit 52-week highs Aug. 10 on trial and earnings updates. Silence Therapeutics (SLN) rose about 29% to $17.58 after Phase 2 SANRECO topline results for divesiran and a reduced Q2 net loss, plus an announced ~$150M ADS offering. AbCellera (ABCL) gained ~34% to $10.01 on Phase 2 ABCL635 data. Cumberland (CPIX) reached $8.45 on Phase 2 Ifetroban progress. Celldex (CLDX) rose to $43.21 on Barzolvolimab Phase 3/2 readouts. Biodesix (BDSX) hit $25.51 after Q2 revenue of $26.9M and FY gui
2 min read
